Inhaled mannitol showed no clear difference in hospitalisations Number of participants experiencing one of more… compared with placebo (moderate certainty).
Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).
The review found no eligible studies for this question.
Inhaled mannitol showed no clear difference in health‐related quality of life measured on the SGRQ Scale from 0 to… compared with placebo (moderate certainty).
Inhaled mannitol showed no clear difference in symptoms Bronchiectasis Symptoms Questionnaire compared with placebo (moderate certainty).
Inhaled mannitol showed no clear difference in lung function FEV1 (L) compared with placebo (moderate certainty).
LABA + ICS leads to lower participants with one or more exacerbations requiring systemic… compared with LTRA + ICS (high certainty).
LABA + ICS probably leads to lower withdrawals for any reason compared with LTRA + ICS (moderate certainty).
LABA + ICS showed no clear difference in serious adverse events compared with LTRA + ICS (moderate certainty).
Subcutaneous omalizumab + steroid probably leads to lower number of participants with at least one exacerbation All asthmatic… compared with placebo + steroid (stable steroid) (moderate certainty).
Subcutaneous omalizumab + steroid probably leads to lower number of participants with at least one exacerbation Moderate to… compared with placebo + steroid (stable steroid) (moderate certainty).
Subcutaneous omalizumab + steroid showed no clear difference in number of participants with at least one exacerbation Severe asthma… compared with placebo + steroid (stable steroid) (low certainty).
Subcutaneous omalizumab + steroid showed no clear difference in mortality 16 to 60 weeks compared with placebo + steroid (stable steroid) (low certainty).
Subcutaneous omalizumab + steroid probably leads to lower hospitalisations 28 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty).